{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T15:14:03Z","timestamp":1761664443656},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T00:00:00Z","timestamp":1660089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T00:00:00Z","timestamp":1660089600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The administration of a third booster dose of messenger ribonucleic acid (mRNA) vaccines against coronavirus disease 2019 (COVID-19) has progressed worldwide. Since January 2022, Japan has faced a nationwide outbreak caused by the Omicron variant, which occurred simultaneously with the progression of mass vaccination with the third booster dose. Therefore, this study evaluated the effectiveness of the third dose of vaccine by reverse transcription-polymerase chain reaction (RT-PCR) test using nasopharyngeal swab samples from adults aged\u2009\u2265\u200918\u00a0years tested after having close contact with COVID-19 cases between January and May 2022. Participants who completed only one dose were excluded from the study. Among the 928 enrolled participants, 139 had never been vaccinated, 609 had completed two doses, 180 had completed three doses before the swab test, and the overall RT-PCR test positivity rate in each group was 48.9%, 46.0%, and 32.2%, respectively. The vaccine effectiveness of the third dose to prevent infection after close contact was approximately 40% (95% confidence interval: 20\u201360%), which was the highest at 10\u201370\u00a0days after receiving the third dose. In conclusion, the effectiveness of the three-dose mRNA COVID-19 vaccine after close contact during the Omicron outbreak is approximately 40%.<\/jats:p>","DOI":"10.1038\/s41598-022-17990-7","type":"journal-article","created":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T10:02:59Z","timestamp":1660125779000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Effectiveness of third vaccine dose for coronavirus disease 2019 during the Omicron variant pandemic: a prospective observational study in Japan"],"prefix":"10.1038","volume":"12","author":[{"given":"Tetsuya","family":"Akaishi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeki","family":"Kushimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukio","family":"Katori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriko","family":"Sugawara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Egusa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaoru","family":"Igarashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motoo","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeo","family":"Kure","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin","family":"Takayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michiaki","family":"Abe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minoru","family":"Ohsawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kota","family":"Ishizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiko","family":"Abe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Imai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yohei","family":"Inaba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Iwamatsu-Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Nishioka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ko","family":"Onodera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadashi","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,8,10]]},"reference":[{"key":"17990_CR1","doi-asserted-by":"publisher","first-page":"e13423","DOI":"10.1111\/eci.13423","volume":"50","author":"JPA Ioannidis","year":"2020","unstructured":"Ioannidis, J. P. A. Global perspective of COVID-19 epidemiology for a full-cycle pandemic. Eur. J. Clin. Invest. 50, e13423\u2013e13423. https:\/\/doi.org\/10.1111\/eci.13423 (2020).","journal-title":"Eur. J. Clin. Invest."},{"key":"17990_CR2","unstructured":"World Health Organization. WHO Coronavirus (COVID-19 Dashboard). https:\/\/covid19.who.int\/ (2022)."},{"key":"17990_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1620\/tjem.2022.J012","volume":"257","author":"T Akaishi","year":"2022","unstructured":"Akaishi, T. et al. Effectiveness of mRNA COVID-19 vaccines in Japan during the Nationwide Pandemic of the Delta Variant. Tohoku J. Exp. Med. 257, 1\u20136. https:\/\/doi.org\/10.1620\/tjem.2022.J012 (2022).","journal-title":"Tohoku J. Exp. Med."},{"key":"17990_CR4","doi-asserted-by":"publisher","first-page":"e92","DOI":"10.1056\/NEJMc2113090","volume":"385","author":"J Lopez Bernal","year":"2021","unstructured":"Lopez Bernal, J., Gower, C. & Andrews, N. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. Reply. N Engl J Med 385, e92. https:\/\/doi.org\/10.1056\/NEJMc2113090 (2021).","journal-title":"Reply. N Engl J Med"},{"key":"17990_CR5","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/s0140-6736(21)00628-0","volume":"397","author":"KRW Emary","year":"2021","unstructured":"Emary, K. R. W. et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012\/01 (B.1.1.7): An exploratory analysis of a randomised controlled trial. Lancet 397, 1351\u20131362. https:\/\/doi.org\/10.1016\/s0140-6736(21)00628-0 (2021).","journal-title":"Lancet"},{"key":"17990_CR6","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/s0140-6736(21)02183-8","volume":"398","author":"SY Tartof","year":"2021","unstructured":"Tartof, S. Y. et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: A retrospective cohort study. Lancet 398, 1407\u20131416. https:\/\/doi.org\/10.1016\/s0140-6736(21)02183-8 (2021).","journal-title":"Lancet"},{"key":"17990_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.lana.2022.100198","author":"SY Tartof","year":"2022","unstructured":"Tartof, S. Y. et al. Effectiveness of a third dose of BNT162b2 mRNA COVID-19 vaccine in a large US health system: A retrospective cohort study. Lancet Reg. Health Am. https:\/\/doi.org\/10.1016\/j.lana.2022.100198 (2022).","journal-title":"Lancet Reg. Health Am."},{"key":"17990_CR8","doi-asserted-by":"publisher","first-page":"139","DOI":"10.15585\/mmwr.mm7104e3","volume":"71","author":"MG Thompson","year":"2022","unstructured":"Thompson, M. G. et al. Effectiveness of a third dose of mRNA vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults during periods of delta and omicron variant predominance\u2014VISION network, 10 states, August 2021\u2013January 2022. MMWR Morb. Mortal. Wkly. Rep. 71, 139\u2013145. https:\/\/doi.org\/10.15585\/mmwr.mm7104e3 (2022).","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"17990_CR9","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1093\/infdis\/jiab556","volume":"225","author":"Y Saciuk","year":"2022","unstructured":"Saciuk, Y., Kertes, J., Shamir Stein, N. & Ekka Zohar, A. Effectiveness of a third dose of BNT162b2 mRNA vaccine. J. Infect. Dis. 225, 30\u201333. https:\/\/doi.org\/10.1093\/infdis\/jiab556 (2022).","journal-title":"J. Infect. Dis."},{"key":"17990_CR10","doi-asserted-by":"publisher","first-page":"118","DOI":"10.15585\/mmwr.mm7104a2","volume":"71","author":"MW Tenforde","year":"2022","unstructured":"Tenforde, M. W. et al. Effectiveness of a third dose of Pfizer-BioNTech and Moderna vaccines in preventing COVID-19 hospitalization among immunocompetent and immunocompromised adults\u2014United States, August-December 2021. MMWR Morb. Mortal. Wkly. Rep. 71, 118\u2013124. https:\/\/doi.org\/10.15585\/mmwr.mm7104a2 (2022).","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"17990_CR11","doi-asserted-by":"publisher","first-page":"304","DOI":"10.7883\/yoken.JJID.2020.061","volume":"73","author":"K Shirato","year":"2020","unstructured":"Shirato, K. et al. Development of genetic diagnostic methods for detection for novel coronavirus 2019(nCoV-2019) in Japan. Jpn. J. Infect. Dis. 73, 304\u2013307. https:\/\/doi.org\/10.7883\/yoken.JJID.2020.061 (2020).","journal-title":"Jpn. J. Infect. Dis."},{"key":"17990_CR12","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1620\/tjem.253.101","volume":"253","author":"T Ishii","year":"2021","unstructured":"Ishii, T. et al. Predictors of SARS-CoV-2 positivity based on RT-PCR swab tests at a drive-through outpatient clinic for COVID-19 screening in Japan. Tohoku J. Exp. Med. 253, 101\u2013108. https:\/\/doi.org\/10.1620\/tjem.253.101 (2021).","journal-title":"Tohoku J. Exp. Med."},{"key":"17990_CR13","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1001\/jama.2022.0470","volume":"327","author":"EK Accorsi","year":"2022","unstructured":"Accorsi, E. K. et al. Association between 3 doses of mRNA COVID-19 vaccine and symptomatic infection caused by the SARS-CoV-2 omicron and delta variants. JAMA 327, 639\u2013651. https:\/\/doi.org\/10.1001\/jama.2022.0470 (2022).","journal-title":"JAMA"},{"key":"17990_CR14","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1016\/S0140-6736(21)02249-2","volume":"398","author":"N Barda","year":"2021","unstructured":"Barda, N. et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: An observational study. Lancet 398, 2093\u20132100. https:\/\/doi.org\/10.1016\/S0140-6736(21)02249-2 (2021).","journal-title":"Lancet"},{"key":"17990_CR15","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1126\/science.abn7591","volume":"375","author":"A Muik","year":"2022","unstructured":"Muik, A. et al. Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera. Science 375, 678\u2013680. https:\/\/doi.org\/10.1126\/science.abn7591 (2022).","journal-title":"Science"},{"key":"17990_CR16","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.arcmed.2020.12.002","volume":"52","author":"JE-dL Pe\u00f1a","year":"2021","unstructured":"Pe\u00f1a, J.E.-dL. et al. Hypertension, diabetes and obesity, major risk factors for death in patients with COVID-19 in Mexico. Arch. Med. Res. 52, 443\u2013449 (2021).","journal-title":"Arch. Med. Res."},{"key":"17990_CR17","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1111\/dom.14228","volume":"23","author":"S Smati","year":"2021","unstructured":"Smati, S. et al. Relationship between obesity and severe COVID-19 outcomes in patients with type 2 diabetes: Results from the CORONADO study. Diabetes Obes. Metab. 23, 391\u2013403. https:\/\/doi.org\/10.1111\/dom.14228 (2021).","journal-title":"Diabetes Obes. Metab."},{"key":"17990_CR18","doi-asserted-by":"publisher","first-page":"154378","DOI":"10.1016\/j.metabol.2020.154378","volume":"113","author":"Y Huang","year":"2020","unstructured":"Huang, Y. et al. Obesity in patients with COVID-19: A systematic review and meta-analysis. Metabolism 113, 154378\u2013154378. https:\/\/doi.org\/10.1016\/j.metabol.2020.154378 (2020).","journal-title":"Metabolism"},{"key":"17990_CR19","doi-asserted-by":"publisher","first-page":"773","DOI":"10.7326\/M20-3742","volume":"173","author":"SY Tartof","year":"2020","unstructured":"Tartof, S. Y. et al. Obesity and mortality among patients diagnosed with COVID-19: Results from an integrated health care organization. Ann. Intern. Med. 173, 773\u2013781. https:\/\/doi.org\/10.7326\/M20-3742 (2020).","journal-title":"Ann. Intern. Med."},{"key":"17990_CR20","doi-asserted-by":"publisher","first-page":"100789","DOI":"10.1016\/j.eclinm.2021.100789","volume":"33","author":"FV Gerayeli","year":"2021","unstructured":"Gerayeli, F. V. et al. COPD and the risk of poor outcomes in COVID-19: A systematic review and meta-analysis. EClinicalMedicine 33, 100789. https:\/\/doi.org\/10.1016\/j.eclinm.2021.100789 (2021).","journal-title":"EClinicalMedicine"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-17990-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-17990-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-17990-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T06:53:46Z","timestamp":1669359226000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-17990-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,10]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["17990"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-17990-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,10]]},"assertion":[{"value":"28 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests<b>.<\/b>","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13589"}}